Experience

Viva Biotech (Shanghai) Ltd.
• China
• Biotechnology
• Vice President of Business Development

  • Sep 2022 - Present

BioDuro-Sundia
• United States
• Biotechnology Research
• 200 - 300 Employee
• Director Of Business Development

  • Mar 2022 - Sep 2022


Paraza Pharma Inc.

• Canada
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Executive Director of Business Development

  • Aug 2020 - Feb 2022

  • Drives the business development aspect of Paraza to promote sustained business growth that is focused on client satisfaction and success through Paraza’s collaborative model of drug discovery. • Conducts research to identify market trends and parlay said knowledge to a viable business growth strategy. • Establish new collaborative relationships with client partners and support existing client relationships. http://parazapharma.com/ • Drives the business development aspect of Paraza to promote sustained business growth that is focused on client satisfaction and success through Paraza’s collaborative model of drug discovery. • Conducts research to identify market trends and parlay said knowledge to a viable business growth strategy. • Establish new collaborative relationships with client partners and support existing client relationships. http://parazapharma.com/



Eisai US

• Pharmaceutical Manufacturing
• 700 & Above Employee

• Director

  • 2016 - 2018

  • Managed team of 8 chemists and responsible for budgets and promotions. • Guided and mentored newly assigned chemistry direct reports to the area of Early Drug Discovery and Medicinal Chemistry. • Established an external collaboration in the Oncology area. • Participated in project meetings suggesting ways to overcome current challenges and avenues for project advancement.

• Director of Chemistry in Oncology

  • 2010 - 2016

  • Led chemistry effort of PDC (Peptide Drug Conjugate) project in which durable cures cures were achieved in mice for prostate and pancreatic human xenografts.• Led team of 12 chemists, responsible for project oversight, milestones, budgets, hiring, and promotions. • Worked extensively with biology, PK and imaging to push discovery programs forward. • Led chemistry aspects of internal ADC-based collaboration.• Established one external collaboration in Oncology. • Implemented and actioned updates on various on-site technologies (uPLCMS, NMR, HPLC).• Hired and supervised temporary and external chemistry FTE resource.• Participated in management level site related meetings. Show less

• Principal Scientist

  • 2008 - 2010

  • Initiated and carried out research on a pre-clinical Peptide Drug Conjugate, based on the naturally occurring chlorotoxin peptide, including linker design, payload selection and appropriate chemical modifications.• Prepared molecules for liposomal formulation and worked with Tsukuba Site Liposomal group.• Initiated, and led synthetic efforts on various complex natural products (aplyronine and neopeltolide) for Oncology programs.

• Scientist

  • 2004 - 2008

  • Synthesis and Biological Evaluation of various Ipomoeassin of natural products and analogs.• Championed the effort in evaluating said compounds for Oncology-based drug discovery.• Functioned as Lead Identification liaison on various projects and provided early discovery support including probe synthesis.



Wayne State University

• United States
• Higher Education
• 700 & Above Employee

• Assistant Professor Of Chemistry

  • 1997 - 2004

  Taught undergraduate and graduate level organic chemistry courses. Our NSF funded research program resulted in the development of successful, robust and methodology for the synthesis of stable carbohydrate mimetics. Taught undergraduate and graduate level organic chemistry courses. Our NSF funded research program resulted in the development of successful, robust and methodology for the synthesis of stable carbohydrate mimetics.



The Scripps Research Institute

• Postdoctoral Research Associate

  • 1994 - 1997

  • Discovered RCM methodology-based approach for the synthesis of cyclic enols and polyethers and its application to the synthesis of a Brevetoxin analog and three Maitotoxin bicyclic fragments. • Designed and executed a sigmatropic-free-radical cyclization approach to the CP natural product core. • Discovered RCM methodology-based approach for the synthesis of cyclic enols and polyethers and its application to the synthesis of a Brevetoxin analog and three Maitotoxin bicyclic fragments. • Designed and executed a sigmatropic-free-radical cyclization approach to the CP natural product core.